Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study
Cancer Treatment Communications · 2013
DOI: 10.1016/j.ctrc.2013.07.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment Communications, 2013. Verfasst von Jan Stoehlmacher-Williams und 5 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Pathology, Medical Faculty Carl Gustav Carus, TU Dresden.
Abstract (Originalsprache)
We present the case of a 27 year old woman with widely disseminated metastatic adenocarcinoma of the lung who outlived stage IV diagnosis of NSCLC by more than 4 years. Based on rebiopsy and molecular diagnostics of oncogene dependency, appropriately targeted therapies were successfully employed up to a fifth line oral monotherapy with the ErbB family blocker afatinib for a final 11 months. We stress the importance of rebiopsies, the corresponding selection of targeted therapies, and the observed gain in quality of live even in end stage disease.
Förderung
- Department of Pathology, Medical Faculty Carl Gustav Carus, TU Dresden
Zitieren
APA
Stoehlmacher-Williams, J., Ehninger, G., Zimmermann, D. R., Merkelbach-Bruse, S., Schildhaus, H., & Buettner, R. (2013). Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study. Cancer Treatment Communications. https://doi.org/10.1016/j.ctrc.2013.07.001
Vancouver
Stoehlmacher-Williams J, Ehninger G, Zimmermann DR, Merkelbach-Bruse S, Schildhaus H, Buettner R. Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study. Cancer Treatment Communications. 2013. doi:10.1016/j.ctrc.2013.07.001
BibTeX
@article{StoehlmacherWilliams2013,
author = {Stoehlmacher-Williams, Jan and Ehninger, Gerhard and Zimmermann, Dieter R. and Merkelbach-Bruse, Sabine and Schildhaus, Hans-Ulrich and Buettner, Reinhard},
title = {Targeting TKI-resistance in NSCLC: Importance of rebiopsy and molecular diagnostics—A case study},
journal = {Cancer Treatment Communications},
year = {2013},
doi = {10.1016/j.ctrc.2013.07.001}
}
EUVIMED